Suchergebnisse - "Specchia, Giorgina"

PubPharm (21)

1

Eutos long-term survival score discriminates different Sokal score categories in chronic myeloid leukemia patients, showing better survival prediction. Analysis of the GIMEMA CML observational study

enthalten in: Leukemia | 2021

von Breccia, M. | Pregno, P. | Castagnetti, F. | +13

2

Ruxolitinib - better prognostic impact in low-intermediate 1 risk score : evaluation of the 'rete ematologica pugliese' (REP) in primary and secondary myelofibrosis

enthalten in: Leukemia & lymphoma | 2017

von Mazza, P. | Specchia, G. | Di Renzo, N. | +10

3

BCR-ABL1 e6a2 transcript in chronic myeloid leukemia : biological features and molecular monitoring by droplet digital PCR

enthalten in: Virchows Archiv : an international journal of pathology | 2015

von Zagaria, A. | Anelli, L. | Coccaro, N. | +12

4

Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors

enthalten in: Haematologica | 2013

von Russo Rossi, A. | Breccia, M. | Abruzzese, E. | +17

5

Additional chromosomal abnormalities in Philadelphia-positive clone : adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis

enthalten in: Blood | 2012

von Luatti, S. | Castagnetti, F. | Marzocchi, G. | +24

ErratumIn: Blood. 2013 Jun 27;121(26):5259 Cambrin, Rege [corrected to Rege-Cambrin, Giovanna]

6

Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib

enthalten in: Haematologica | 2011

von Breccia, M. | Latagliata, R. | Stagno, F. | +17

CommentIn: Haematologica. 2011 Oct;96(10):1395-7. - PMID 21972208

7

Variant Philadelphia translocations : molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis

enthalten in: Blood | 2011

von Marzocchi, G. | Castagnetti, F. | Luatti, S. | +23

CommentIn: Blood. 2011 Jun 23;117(25):6741-2. - PMID 21700778

8

Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients

enthalten in: American journal of hematology | 2010

von Visani, G. | Breccia, M. | Gozzini, A. | +12

9

Adherence to international guidelines for the treatment of invasive aspergillosis in acute myeloid leukaemia : feasibility and utility (SEIFEM-2008B study)

enthalten in: The Journal of antimicrobial chemotherapy | 2010

von Pagano, L. | Caira, M. | Offidani, M. | +9

10

The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone : a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase

enthalten in: Haematologica | 2010

von Palandri, F. | Castagnetti, F. | Iacobucci, I. | +17